NASDAQ:CDXC ChromaDex (CDXC) Stock Forecast, Price & News $1.59 +0.02 (+1.27%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$1.57▼$1.6150-Day Range$1.31▼$1.5952-Week Range$1.15▼$2.37Volume68,732 shsAverage Volume149,893 shsMarket Capitalization$119.20 millionP/E RatioN/ADividend YieldN/APrice Target$4.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ChromaDex MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside187.2% Upside$4.57 Price TargetShort InterestBearish3.80% of Float Sold ShortDividend StrengthN/ASustainability-1.55Upright™ Environmental ScoreNews Sentiment0.01Based on 11 Articles This WeekInsider TradingAcquiring Shares$20,160 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.14) to ($0.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector313th out of 986 stocksMedicinals & Botanicals Industry2nd out of 11 stocks 3.2 Analyst's Opinion Consensus RatingChromaDex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.57, ChromaDex has a forecasted upside of 187.2% from its current price of $1.59.Amount of Analyst CoverageChromaDex has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.80% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in ChromaDex has recently decreased by 3.14%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldChromaDex does not currently pay a dividend.Dividend GrowthChromaDex does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChromaDex has received a 63.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Dietary supplements" products. See details.Environmental SustainabilityThe Environmental Impact score for ChromaDex is -1.55. Previous Next 2.2 News and Social Media Coverage News SentimentChromaDex has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for ChromaDex this week, compared to 2 articles on an average week.Search Interest6 people have searched for CDXC on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChromaDex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,160.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.57% of the stock of ChromaDex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.81% of the stock of ChromaDex is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ChromaDex are expected to grow in the coming year, from ($0.14) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChromaDex is -10.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChromaDex is -10.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChromaDex has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ChromaDex (NASDAQ:CDXC) StockChromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Read More Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXC Stock News HeadlinesJune 8, 2023 | finance.yahoo.comIt's A Story Of Risk Vs Reward With ChromaDex Corporation (NASDAQ:CDXC)June 8, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for ChromaDex Co. Decreased by Analyst (NASDAQ:CDXC)June 9, 2023 | Vector Vest (Ad)Master Market Movements: Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights!Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. June 5, 2023 | msn.comHC Wainwright & Co. Reiterates Chromadex (CDXC) Buy RecommendationJune 5, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Chromadex (CDXC)June 3, 2023 | americanbankingnews.comStockNews.com Downgrades ChromaDex (NASDAQ:CDXC) to BuyJune 2, 2023 | americanbankingnews.comInsider Buying: ChromaDex Co. (NASDAQ:CDXC) Director Purchases $10,220.00 in StockMay 30, 2023 | finance.yahoo.comChromaDex to Participate in the LD Micro Invitational XIIIJune 9, 2023 | Vector Vest (Ad)Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 26, 2023 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Stock Rating Upgraded by StockNews.comMay 17, 2023 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Rating Increased to Strong-Buy at StockNews.comMay 14, 2023 | americanbankingnews.comLADENBURG THALM/SH SH Trims ChromaDex (NASDAQ:CDXC) Target Price to $6.60May 11, 2023 | msn.comRecap: ChromaDex Q1 EarningsMay 11, 2023 | finance.yahoo.comChromaDex to Present at the Lytham Partners Spring 2023 Investor ConferenceMay 10, 2023 | finance.yahoo.comChromaDex Corporation Reports First Quarter 2023 Financial ResultsMay 8, 2023 | americanbankingnews.comChromaDex (CDXC) Scheduled to Post Earnings on WednesdayMay 2, 2023 | finance.yahoo.comChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023April 29, 2023 | ca.finance.yahoo.comChromaDex Corporation (CDXC) Interactive Stock Chart - Yahoo FinanceApril 12, 2023 | finance.yahoo.comIndividual investors account for 44% of ChromaDex Corporation's (NASDAQ:CDXC) ownership, while insiders account for 26%April 3, 2023 | americanbankingnews.comChromaDex Co. (NASDAQ:CDXC) Short Interest Down 6.7% in MarchMarch 27, 2023 | finance.yahoo.comBullish ChromaDex Corporation (NASDAQ:CDXC) insiders filled their treasuries with US$1.6m worth of stock over last yearMarch 10, 2023 | finance.yahoo.comChromaDex Full Year 2022 Earnings: EPS Misses ExpectationsMarch 10, 2023 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | finance.yahoo.comChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 ResultsMarch 6, 2023 | finance.yahoo.comChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023February 27, 2023 | finance.yahoo.comChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023February 22, 2023 | finance.yahoo.comChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor SpaceSee More Headlines CDXC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXC Company Calendar Last Earnings3/08/2023Today6/09/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDXC CUSIPN/A CIK1386570 Webwww.chromadex.com Phone(310) 388-6706Fax949-419-0294Employees115Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.57 High Stock Price Forecast$6.60 Low Stock Price Forecast$2.10 Forecasted Upside/Downside+184.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,540,000.00 Net Margins-13.84% Pretax Margin-13.84% Return on Equity-51.99% Return on Assets-25.59% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio1.88 Sales & Book Value Annual Sales$72.05 million Price / Sales1.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book4.12Miscellaneous Outstanding Shares74,970,000Free Float67,042,000Market Cap$120.33 million OptionableOptionable Beta1.79 Key ExecutivesRobert N. FriedChief Executive Officer & DirectorBrianna GerberChief Financial OfficerFadi KaramChief Marketing OfficerTrent CraneRegional Vice President-SalesHeather Van BlarcomSecretary & Senior Vice President-LegalKey CompetitorsMind Medicine (MindMed)NASDAQ:MNMDBright GreenNASDAQ:BGXXUpexiNASDAQ:GRVINatural Alternatives InternationalNASDAQ:NAIIAurora CannabisNYSE:ACBView All CompetitorsInsiders & InstitutionsRobert N FriedBought 7,000 shares on 5/31/2023Total: $9,940.00 ($1.42/share)Steven D RubinBought 7,000 shares on 5/25/2023Total: $10,220.00 ($1.46/share)State Street CorpBought 13,400 shares on 5/16/2023Ownership: 0.254%Susquehanna International Group LLPBought 108,947 shares on 5/16/2023Ownership: 0.145%Squarepoint Ops LLCBought 17,983 shares on 5/16/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions CDXC Stock - Frequently Asked Questions Should I buy or sell ChromaDex stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CDXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDXC, but not buy additional shares or sell existing shares. View CDXC analyst ratings or view top-rated stocks. What is ChromaDex's stock price forecast for 2023? 3 brokers have issued 1 year price objectives for ChromaDex's shares. Their CDXC share price forecasts range from $2.10 to $6.60. On average, they predict the company's stock price to reach $4.57 in the next twelve months. This suggests a possible upside of 184.5% from the stock's current price. View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts. How have CDXC shares performed in 2023? ChromaDex's stock was trading at $1.68 at the beginning of the year. Since then, CDXC shares have decreased by 4.5% and is now trading at $1.6050. View the best growth stocks for 2023 here. When is ChromaDex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our CDXC earnings forecast. How were ChromaDex's earnings last quarter? ChromaDex Co. (NASDAQ:CDXC) issued its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. The company earned $21 million during the quarter, compared to analysts' expectations of $21.08 million. ChromaDex had a negative trailing twelve-month return on equity of 51.99% and a negative net margin of 13.84%. During the same quarter in the prior year, the firm earned ($0.08) EPS. What guidance has ChromaDex issued on next quarter's earnings? ChromaDex issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $81.06M-, compared to the consensus revenue estimate of $82.65 million. What is Robert Fried's approval rating as ChromaDex's CEO? 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend. What other stocks do shareholders of ChromaDex own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL). What is ChromaDex's stock symbol? ChromaDex trades on the NASDAQ under the ticker symbol "CDXC." Who are ChromaDex's major shareholders? ChromaDex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Tieton Capital Management LLC (3.41%), BlackRock Inc. (1.20%), Renaissance Technologies LLC (0.57%), GMT Capital Corp (0.40%), Cambridge Investment Research Advisors Inc. (0.26%) and State Street Corp (0.25%). Insiders that own company stock include Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Kevin M Farr, Robert N Fried, Stephen A Block and Steven D Rubin. View institutional ownership trends. How do I buy shares of ChromaDex? Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ChromaDex's stock price today? One share of CDXC stock can currently be purchased for approximately $1.61. How much money does ChromaDex make? ChromaDex (NASDAQ:CDXC) has a market capitalization of $120.33 million and generates $72.05 million in revenue each year. The company earns $-16,540,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. How many employees does ChromaDex have? The company employs 115 workers across the globe. How can I contact ChromaDex? ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The official website for the company is www.chromadex.com. The company can be reached via phone at (310) 388-6706, via email at investorrelations@chromadex.com, or via fax at 949-419-0294. This page (NASDAQ:CDXC) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.